$5.13-0.30 (-5.52%)
LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, weight management, pre and pro-biotics and skin and hair care products internationally.
LifeVantage Corporation in the Consumer Defensive sector is trading at $5.13. The stock is currently near its 52-week low of $3.90, remaining 32.7% below its 200-day moving average. Technical signals show neutral RSI of 67 and bullish MACD crossover, explaining why LFVN maintains its current current market pressure. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, weight management, pre and pro-biotics and skin and hair care products internati...
Analysts have cut their price target on LifeVantage by $7, even as the fair value marker in their updated work holds at $8.0. That shift reflects a reset in expectations that, according to recent commentary, incorporates more caution around earnings power and execution risk while still leaving room for differing views on potential upside. As you read on, you will see how this revised target fits into the evolving analyst story around risk, reward, and what might matter most next for...
Lifevantage (LFVN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
In the last week, the market has been flat, but over the past 12 months, it has risen by 30%, with earnings expected to grow by 16% annually in the coming years. In this context, identifying stocks with strong financial health is crucial for investors looking to capitalize on growth opportunities. Although the term "penny stocks" might seem outdated, these shares often represent smaller or newer companies that can offer significant value and growth potential when backed by solid fundamentals.
The market has climbed 1.7% in the last 7 days and an impressive 34% over the past year, with earnings forecasted to grow by 16% annually. Investing in penny stocks—typically associated with smaller or newer companies—can still open doors to growth opportunities, especially when these stocks are supported by strong financial health. This article explores several promising penny stocks that combine balance sheet strength with long-term potential for investors seeking underappreciated growth...
Over the last 7 days, the U.S. market has risen by 1.7%, and in the past year, it has climbed 34%, with earnings forecast to grow by 16% annually. Penny stocks might seem like a relic of past market eras, but they still hold potential when backed by strong financials, offering affordability and growth opportunities that larger firms may overlook. In this article, we'll explore three penny stocks that stand out for their financial strength and potential to offer compelling opportunities for...